This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
- ENI (ENI) significantly surpassed analyst expectations for Q3 2025 adjusted net income and operating profit, driven by robust production figures.
- Sanofi (SAN) reported strong Q3 2025 earnings, with business EPS and sales exceeding estimates, notably boosted by Dupixent sales.
- Japan's retail sector presented a mixed picture in September, with Tokyo department store sales rebounding to 2.5% year-over-year growth, while nationwide sales growth slowed to 1.4%.
Italian energy giant ENI (ENI) and French pharmaceutical major Sanofi (SAN) both reported stronger-than-expected third-quarter 2025 earnings, signaling solid operational performance in their respective sectors. Meanwhile, Japan's retail landscape displayed contrasting trends in September, with a rebound in Tokyo department store sales juxtaposed against a slowdown in nationwide growth.
ENI's Strong Q3 Performance
ENI (ENI) delivered a robust third quarter, with adjusted net income reaching €1.25 billion, significantly outperforming analyst estimates of €1.01 billion. The company's adjusted operating profit also exceeded expectations, coming in at €2.07 billion against an estimated €1.89 billion.
This strong financial showing was supported by solid production, which stood at 1.76 million barrels of oil equivalent per day (boe/d), surpassing the estimated 1.72 million boe/d. The Enilive & Plenitude segment contributed €333 million in adjusted operating profit. The company anticipates its full-year production to range between 1.71 million and 1.72 million boe/d.
Sanofi Beats Estimates on Key Metrics
Sanofi (SAN) also posted impressive Q3 2025 results, with business earnings per share (EPS) reported at €2.91, comfortably beating the estimated €2.65. The pharmaceutical firm's business operating income reached €4.45 billion, exceeding the €4.13 billion consensus.
Total sales for the quarter were €12.43 billion, slightly above the €12.36 billion estimate, with sales at constant exchange rates growing by 7%. A significant driver of this growth was Dupixent, Sanofi's key immunology drug, which recorded net product sales of €4.16 billion, surpassing the €4.01 billion estimate. Notably, research and development expenses were €1.83 billion, lower than the anticipated €1.94 billion.
Mixed Signals from Japan's Retail Sector
Japan's department store sales in September presented a nuanced picture of consumer spending. While Tokyo department store sales saw a positive turnaround, growing 2.5% year-over-year, reversing the previous month's -2.3% decline, nationwide sales growth slowed.
Nationwide department store sales increased by 1.4% year-over-year in September, a noticeable deceleration from the 2.6% growth recorded in the previous month. This mixed performance suggests regional variations in consumer confidence and spending patterns across Japan.
Automated market updates written with AI from market data and news wire reports, published without human review.